Associated Malignancies in Patients with Waldenstrom's Macroglobulinemia and Their Kin
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom's Macroglobulinemia
Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia
Hepcidin is Produced by Lymphoplasmacytic Cells and is Associated With Anemia in Waldenstrom's Macroglobulinemia
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia
How I treat the acquired von Willebrand syndrome
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenström macroglobulinemia
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
Maintenance Rituximab is associated with improved clinical outcome in rituximab naı¨ve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
Matrix Metalloproteinase-8 Is Overexpressed in Waldenström's Macroglobulinemia Cells, and Specific Inhibition of this Metalloproteinase Blocks Release of Soluble CD27
Report from the Sixth International Workshop on Waldenstrom's Macroglobulinemia
To Treat or Not To Treat, This is the Real Question
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells